Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
Earnings Preview: EW to Report Financial Results Post-market on July 24
$Edwards Lifesciences(EW.US)$ is scheduled to release its financial results post-market on July 24. Earnings PreviewAnalysts estimate $Edwards Lifesciences(EW.US)$ to post revenue of USD1.65 billion
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
Is Edwards Lifesciences Corporation (NYSE:EW) Worth US$87.3 Based On Its Intrinsic Value?
Key Insights Edwards Lifesciences' estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current share price of US$87.31 suggests Edwards Lifesciences is potentially 25%
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 22.22% Truist Securities $105 → $110 Maintains Buy 07/10/2024 17.78% Citigroup $105 → $106
Truist Financial Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $110
Truist Financial analyst Richard Newitter maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and sets the target price at $110.According to TipRanks data, the analyst has a success rate of 58.
Express News | Edwards Lifesciences Corp : Truist Securities Raises Target Price to $110 From $105
Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating
06:57 AM EDT, 07/16/2024 (MT Newswires) -- Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy RatingPrice: 89.85, Change: +0.35, Percent Change: +0.39
Edwards Lifesciences Buys Mitral Valve Business Innovalve in $300m Deal
BTIG Maintains Edwards Lifesciences(EW.US) With Hold Rating
BTIG analyst Marie Thibault maintains $Edwards Lifesciences(EW.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 32.5% and a total average return of -1.5% over
Maintaining Hold on Edwards Lifesciences Amid Strategic Expansion and Product Development
Sector Update: Health Care Stocks Retreat Monday Afternoon
Health care stocks fell Monday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was little
Sector Update: Health
Health care stocks were slipping Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%.The iShares Biotechnology ETF (IBB)
Top Midday Stories: Trump Media & Technology Group Shares Rise After Ex-President Trump Survives Assassination Attempt; Goldman Sachs, BlackRock Q2 Earnings Gain; Edwards Lifesciences to Acquire Innovalve Bio Medical
Wall Street's major market averages were trading higher Monday afternoon, the first trading day after the assassination attempt on former US President Donald Trump.Shares of Trump Media & Technology
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Express News | Edwards Lifesciences: To Pay Consideration of About $300 Mln in Cash for Deal With Innovalve
Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102
Edwards Lifesciences (EW) has an average outperform rating and price target range of $70 to $107, according to analysts polled by Capital IQ.Price: 91.50, Change: +0.51, Percent Change: +0.56